tetano
Editor, Senior Moderator
Front Immunol
. 2021 Dec 6;12:766112.
doi: 10.3389/fimmu.2021.766112. eCollection 2021.
Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
Thi Nhu Mai Tran[SUP] 1 [/SUP], Bruce Pearson May[SUP] 1 [/SUP], Trong Thuan Ung[SUP] 1 [/SUP], Mai Khoi Nguyen[SUP] 1 [/SUP], Thi Thuy Trang Nguyen[SUP] 1 [/SUP], Van Long Dinh[SUP] 1 [/SUP], Chinh Chung Doan[SUP] 1 [/SUP], The Vinh Tran[SUP] 1 [/SUP], Hiep Khong[SUP] 1 [/SUP], Thi Thanh Truc Nguyen[SUP] 1 [/SUP], Hoang Quoc Huy Hua[SUP] 1 [/SUP], Viet Anh Nguyen[SUP] 1 [/SUP], Tan Phat Ha[SUP] 1 [/SUP], Dang Luu Phan[SUP] 1 [/SUP], Truong An Nguyen[SUP] 1 [/SUP], Thi Ngoc Bui[SUP] 1 [/SUP], Tieu My Tu[SUP] 1 [/SUP], Thi Theo Nguyen[SUP] 1 [/SUP], Thi Thuy Hang Le[SUP] 1 [/SUP], Thi Lan Dong[SUP] 1 [/SUP], Trong Hieu Huynh[SUP] 1 [/SUP], Phien Huong Ho[SUP] 1 [/SUP], Nguyen Thanh Thao Le[SUP] 1 [/SUP], Cong Thao Truong[SUP] 1 [/SUP], Hoang Phi Pham[SUP] 1 [/SUP], Cong Y Luong[SUP] 1 [/SUP], Nie Lim Y[SUP] 1 [/SUP], Minh Ngoc Cao[SUP] 1 [/SUP], Duy Khanh Nguyen[SUP] 1 [/SUP], Thi Thanh Le[SUP] 2 [/SUP], Duc Cuong Vuong[SUP] 2 [/SUP], Le Khanh Hang Nguyen[SUP] 2 [/SUP], Minh Si Do[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (Macaca leonina). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
Keywords: ACE2; CHO; COVID-19; RBD; SARS-CoV-2.
. 2021 Dec 6;12:766112.
doi: 10.3389/fimmu.2021.766112. eCollection 2021.
Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
Thi Nhu Mai Tran[SUP] 1 [/SUP], Bruce Pearson May[SUP] 1 [/SUP], Trong Thuan Ung[SUP] 1 [/SUP], Mai Khoi Nguyen[SUP] 1 [/SUP], Thi Thuy Trang Nguyen[SUP] 1 [/SUP], Van Long Dinh[SUP] 1 [/SUP], Chinh Chung Doan[SUP] 1 [/SUP], The Vinh Tran[SUP] 1 [/SUP], Hiep Khong[SUP] 1 [/SUP], Thi Thanh Truc Nguyen[SUP] 1 [/SUP], Hoang Quoc Huy Hua[SUP] 1 [/SUP], Viet Anh Nguyen[SUP] 1 [/SUP], Tan Phat Ha[SUP] 1 [/SUP], Dang Luu Phan[SUP] 1 [/SUP], Truong An Nguyen[SUP] 1 [/SUP], Thi Ngoc Bui[SUP] 1 [/SUP], Tieu My Tu[SUP] 1 [/SUP], Thi Theo Nguyen[SUP] 1 [/SUP], Thi Thuy Hang Le[SUP] 1 [/SUP], Thi Lan Dong[SUP] 1 [/SUP], Trong Hieu Huynh[SUP] 1 [/SUP], Phien Huong Ho[SUP] 1 [/SUP], Nguyen Thanh Thao Le[SUP] 1 [/SUP], Cong Thao Truong[SUP] 1 [/SUP], Hoang Phi Pham[SUP] 1 [/SUP], Cong Y Luong[SUP] 1 [/SUP], Nie Lim Y[SUP] 1 [/SUP], Minh Ngoc Cao[SUP] 1 [/SUP], Duy Khanh Nguyen[SUP] 1 [/SUP], Thi Thanh Le[SUP] 2 [/SUP], Duc Cuong Vuong[SUP] 2 [/SUP], Le Khanh Hang Nguyen[SUP] 2 [/SUP], Minh Si Do[SUP] 1 [/SUP]
Affiliations
- PMID: 34938290
- PMCID: PMC8685539
- DOI: 10.3389/fimmu.2021.766112
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (Macaca leonina). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
Keywords: ACE2; CHO; COVID-19; RBD; SARS-CoV-2.